|Gene Symbol||Gene Title||Synonyms||Gene function|
|NFKBIA||nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha||IkappaB-alpha, IkB-a, IkBa, Inhibitor of kappa B-alpha, MAD3, P40||
Proliferation in HT1080 cells is mediated through a NFKB dependent pathways [29, 54].|
Tumor invasiveness could be significantly reduced in HT1080 cells by reducing NFKB activity .
Increased NFKB activity leads to doxorubicin resistance in a p53 dependent manner .
|HSPA1A/B||heat shock 70 kDa protein 1A/B||HSP70, HSP72, HSPA1||
Upregulation of HSPA1A significantly increased chemosensitivity of HT1080 to mitomycin C .|
The apoptogenic effects of taxanes on sarcoma could be increased by co-therapy with stimulators of HSPA1A expression .
|SGK||serum/glucocorticoid regulated kinase||serine/threonine-protein kinase Sgk1, serum/glucocorticoid-regulated kinase 1, SGK1||SGK activates the NFKB pathway and thereby can prevent cells from undergoing apoptosis .|
|GADD45A||growth arrest and DNA-damage-inducible, alpha||DDIT1, DNA-damage-inducible transcript 1, GADD45, Growth arrest and DNA-damage-inducible protein, GADD45 alpha||
Upregulation of GADD45A is associated with increased apoptosis and cell cycle arrest p53 independently in a variety of soft tissue sarcomas .|
It inhibits transcription factors associated with tumor growth including the c-Jun N-terminal kinase (JNK) cascade and NFKB [38, 39, 41, 55].
For rhabdomyosarcoma, increased GADD45A expression was associated with less aggressive tumor behaviour .
GADD45 may antagonize TNF-receptor mediated cytotoxicity .
|ARHGDIA||Rho GDP dissociation inhibitor (GDI) alpha||GDIA1, MGC117248, RHOGDI, Rho GDI 1, Rho-GDI alpha, Rho GDP-dissociation inhibitor 1||
High levels of Rho-GTP are detected in HT1080 cells. The inhibition of Rho by fasudil, a Rho kinase inhibitor lead to decreased tumor cell motility and growth in HT1080 cells  and associated to the development of metastases in several other malignant tumors [23, 24].|
ARHGDIA is downregulated by doxorubicin in HT1080 cells .
|PPP1R15A||protein phosphatase 1, regulatory (inhibitor) subunit 15A||GADD34, MyD116||Increased expression of PPP1R15A by chemosensitizers can potentiate the effects of cytostatics such as platinum agents  and probably acts p53 independently .|
|MYC||v-myc myelocytomatosis viral oncogene homolog (avian)||c-Myc, Myc proto-oncogene protein, transcription factor p64||Myc induces apoptosis by increasing the p53 levels JNK-dependently .|
|AXL||AXL receptor tyrosine kinase||oncogene tyrosine-protein kinase receptor UFO precursor, UFO||
AXL is associated with metastatic potential of malignant cells by regulating adherence, motility, and invasiveness .|
It can prevent cells from TNFalpha mediated cell death via the phosphatidylinositol 3-kinase  and the NFKB pathway .
|MAP3K14||mitogen-activated protein kinase kinase kinase 14||FTDCR1B, HS, HsNIK, HSNIK, mitogen-activated protein kinase kinase kinase 14, NF-kappa beta-inducing kinase, NIK, serine/threonine-protein kinase NIK||MAP3K14 is a member of the TNF-Pathway and activates NFKB (IKKalpha) . The MAPkinase pathway can induce apoptosis by induction of the GADD family of genes (GADD 34, GADD 45) .|
|BIRC3||baculoviral IAP repeat-containing 3||AIP1, API2, apoptosis inhibitor 2, Baculoviral IAP repeat-containing protein 3, cIAP2, CIAP2, C-IAP2, HAIP1, HIAP1, hiap-1, HIAP-1, IAP1, IAP homolog C, inhibitor of apoptosis protein 1, MALT2, MIHC, RNF49, TNFR2-TRAF signalling complex protein 1||BIRC3 is associated with chemotherapy resistance in Ewing sarcoma, rhabdomyosarcoma  and prostatic cancer  and suppresses TNFalpha mediated cell death by preventing formation of TNF Receptor 1. It regulates pro-survival NFKB-signalling by promoting degradation of MAP3K14 .|
|CALR||calreticulin||calregulin, calreticulin precursor, cC1qR, CRP55, CRTC, ERp60, FLJ26680, grp60, HACBP, RO, SSA||Calreticulin belongs to the family of heat shock proteins and strongly binds to TRAIL . Calreticulin is translocated to tumor cells' membranes after anthracyline therapy and stimulates the anti-tumor immune response .|
|DUSP1||dual specificity phosphatase 1||CL100, dual specificity protein phosphatase 1, dual specificity protein phosphatase hVH1, HVH1, MAP kinase phosphatase 1, MKP1, MKP-1, protein-tyrosine phosphatase CL100, PTPN10, VH1||DUSP inactivates MAP kinases  and can protect cells from apoptotic stimuli by chemotherapeutics .|
|JUN||v-jun sarcoma virus 17 oncogene homolog||activator protein 1, AP1, p39, proto-oncogene c-jun, transcription factor AP-1, V-jun avian sarcoma virus 17 oncogene homolog||
Jun is activated by TRAIL JNK dependently and promotes apoptotic cell death in malignant cells including osteosarcoma .|
Downregulation of JUN decreases the expression of matrix metalloproteinases and thereby cellular invasiveness in HT1080 cells . This down-regulation may be mediated through suppression off NFKB activation .
JUN is known to be a product of MAP2K4-activation and to mediate apoptosis by several chemotherapeutics .
upregulation of HSPA1A and JUN expression Chemosensitivity of HT1080 to mitomycin C could significantly be increased by .
|IRF1||interferon regulatory factor 1||MAR||IRF1 inhibits cell growth and induces apoptosis via activation of caspases 1 and 7 . It inhibits NFKB-dependent activation of matrix metalloproteinase-9 (MMP9) .|
|TNFAIP3||tumor necrosis factor, alpha-induced protein 3||A20, MGC104522, MGC138687, MGC138688, Putative DNA-binding protein A20, TNFA1P2, Zinc finger protein A20||TNFAIP3 down-regulates the TNF-α-induced NFKB signalling pathway  and reduces TNF mediated apoptosis and necrosis .|
|BAG5||BCL2-associated athanogene 5||BAG-5, BAG family molecular chaperone regulator 5, KIAA0873||BAG family members inhibit Hsp70 and promote cell growth and survival .|
|CLK4||CDC-like kinase 4||Dual specificity protein kinase CLK4||CLK family members prevent cells from undergoing intrinsic apoptosis .|
|MET||met proto-oncogene (hepatocyte growth factor receptor)||c-Met, Hepatocyte growth factor receptor precursor, HGF/SF receptor, HGFR, HGF receptor, Met proto-oncogene tyrosine kinase, RCCP2, Scatter factor receptor, SF receptor||Over-expression of MET was associated with enhanced proliferation and aggressive tumor biology in sarcomas. Survival, anchorage dependent growth and invasiveness of sarcoma cells are dependent on MET .|
|MCL1||Myeloid cell leukemia sequence 1 (BCL2-related)||Bcl-2-related protein EAT/mcl1, EAT, Induced myeloid leukemia cell differentiation protein Mcl-1, mcl1/EAT, MCL1L, MCL1S, MGC104264, MGC1839, TM||MCL1 is expressed in a variety of soft tissue sarcomas and acts anti-apoptotic. Inhibition of MCL1 in combination with low dose cyclophosphamide significantly increases apoptosis in HT1080 cells .|
|MAP3K1||mitogen-activated protein kinase kinase kinase 1||MAPK/ERK kinase kinase 1, MAPKKK1, MEKK, MEKK1, MEKK 1, MEK kinase 1||MEKK is activating MAPK and JNK. Reduction of MEKK activity amplifies the apoptotic effect of TNFalpha on fibrosarcoma cells .|
|CASP2||caspase 2, apoptosis-related cysteine peptidase (neural precursor cell expressed, developmentally down-regulated 2)||apoptosis-related cysteine peptidase (neural precursor cell expressed, developmentally down-regulated 2), CASP-2, Caspase-2 precursor, ICH1, ICH-1L, ICH-1L/1S, ICH-1 protease, NEDD2||Casp2 is a member of the caspases family and mediates apoptotic cell death NFKB and Jun dependently but independent from Fas .|